T Cells and Macrophages Drive Pathogenesis of Immune Checkpoint Inhibitor Myocarditis

HomeCirculationVol. 149, No. 1T Cells and Macrophages Drive Pathogenesis of Immune Checkpoint Inhibitor Myocarditis No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextT Cells and Macrophages Drive Pathogenesis of Immune Checkpoint Inhibitor Myocarditis Daniela Čiháková Daniela ČihákováDaniela Čiháková Correspondence to: Daniela Čiháková, 720 Rutland Ave, Ross 648, Baltimore, MD 21205. Email E-mail Address: [email protected] https://orcid.org/0000-0002-8713-2860 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD. W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. Originally published28 Dec 2023https://doi.org/10.1161/CIRCULATIONAHA.123.067189Circulation. 2024;149:67–69This article is a commentary on the followingExpansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor MyocarditisFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 69.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Daniela Čiháková, 720 Rutland Ave, Ross 648, Baltimore, MD 21205. Email cihakova@jhmi.eduREFERENCES1. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.Nat Rev Clin Oncol. 2022; 19:37–50. doi: 10.1038/s41571-021-00552-7CrossrefMedlineGoogle Scholar2. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.Lancet. 2018; 391:933. doi: 10.1016/S0140-6736(18)30533-6CrossrefMedlineGoogle Scholar3. Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem JE, Wu SM, Moslehi JJ, Zhu H. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure.Annu Rev Pharmacol Toxicol. 2021; 61:113–134. doi: 10.1146/annurev-pharmtox-010919-023451CrossrefMedlineGoogle Scholar4. Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.JAMA Netw Open. 2020; 3:e200423. doi: 10.1001/jamanetworkopen.2020.0423CrossrefMedlineGoogle Scholar5. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med. 2022; 386:24–34. doi: 10.1056/NEJMoa2109970CrossrefMedlineGoogle Scholar6. Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis.Nature. 2022; 611:818–826. doi: 10.1038/s41586-022-05432-3CrossrefMedlineGoogle Scholar7. Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, Talor MV, Lasrado N, Reddy J, Cihakova D. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.Cell Rep. 2022; 41:111611. doi: 10.1016/j.celrep.2022.111611CrossrefMedlineGoogle Scholar8. Rieckmann M, Delgobo M, Gaal C, Buchner L, Steinau P, Reshef D, Gil-Cruz C, Horst ENT, Kircher M, Reiter T, et al. Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses.J Clin Invest. 2019; 129:4922–4936. doi: 10.1172/JCI123859CrossrefMedlineGoogle Scholar9. Dick SA, Macklin JA, Nejat S, Momen A, Clemente-Casares X, Althagafi MG, Chen J, Kantores C, Hosseinzadeh S, Aronoff L, et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction.Nat Immunol. 2019; 20:29–39. doi: 10.1038/s41590-018-0272-2CrossrefMedlineGoogle Scholar10. Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C, et al. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury.Circ Res. 2019; 124:263–278. doi: 10.1161/CIRCRESAHA.118.314028LinkGoogle Scholar11. Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Kass DA, Bedja D, Zhang H, Sheikh A, Margolick JB, et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy.J Exp Med. 2014; 211:1449–1464. doi: 10.1084/jem.20132126CrossrefMedlineGoogle Scholar12. Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis.Circulation. 2024; 149:48–66. doi: 10.1161/CIRCULATIONAHA.122.062551LinkGoogle Scholar13. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade.Clin Cancer Res. 2020; 26:487–504. doi: 10.1158/1078-0432.CCR-19-1868CrossrefMedlineGoogle Scholar14. Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, Boussouar S, Nguyen LS, Procureur A, Stein F, et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis.Cancer Discov. 2023; 13:1100–1115. doi: 10.1158/2159-8290.CD-22-1180CrossrefMedlineGoogle Scholar15. Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini PL, Palladini A. IFN-gamma and CD38 in hyperprogressive cancer development.Cancers (Basel). 2021; 13:309. doi: 10.3390/cancers13020309CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesExpansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor MyocarditisPan Ma, et al. Circulation. 2024;149:48-66 January 2, 2024Vol 149, Issue 1 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.067189PMID: 38153995 Originally publishedDecember 28, 2023 KeywordsEditorialsimmune checkpoint inhibitorsmacrophagesmyocarditisT-lymphocytesPDF download Advertisement SubjectsInflammation